Please ensure Javascript is enabled for purposes of website accessibility

Monsanto's New Challenge

By Brian Gorman – Updated Nov 15, 2016 at 5:41PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The ag-biotech firm faces new competitive pressures from rivals and an ongoing wariness of GM crops in Europe.

Monsanto (NYSE:MON) has been a major investor in genetically modified (GM) crops, and that investment has generated a lot of green for the company. In the U.S., the largest market for the agricultural technology outfit, it has grown its share in corn seeds in particular, so now it's the market leader with a 51% share. It's an impressive business -- Monsanto's corn seed and traits segment brought in $1.08 billion in sales in the first six months of this fiscal year.

But two of the company's rivals, Syngenta (NYSE:SYT) and DuPont (NYSE:DD), have recently formed an alliance to counteract Monsanto's dominance. This step, when viewed in light of other developments, suggests that Monsanto will have a tougher time keeping its perch as the world leader of agricultural biotechnology.

Syngenta and DuPont announced earlier this week that they will pool their genetic traits for corn and soybeans in a 50/50 joint venture known as GreenLeaf Genetics LLC. The venture will offer out-licensing for various genetic traits to seed companies in the U.S. and Canada. In addition, the companies agreed to cross-license technology so that Syngenta will get rights to DuPont's Optimum GAT, which, like Monsanto's Roundup Ready trait, makes crops tolerant to insecticides, while DuPont will get access to Syngenta traits for insect resistance.

Even as Monsanto's rivals team up to challenge its leadership in the U.S., Monsanto's potential for expansion is being stymied by the European Union. The European Commission recently proposed making the approval process for GM crops even tougher. It seems that for the foreseeable future, Monsanto will have to rely on U.S. sales, and with the new alliance, the competition just got tougher.

Meanwhile, Syngenta recently announced that it's pumping up its efforts to find new innovations in plant technology. The European firm recently launched a $100 million fund to invest in companies involved in such areas as crop technology and protection.

Neither Syngenta and DuPont's alliance nor Syngenta's investment plans signals a death knell for Monsanto, but Monsanto is now looking at a more level playing field in the U.S., even as its potential for expansion remains checked by ongoing concerns over GM organisms.

Fool contributor Brian Gorman is a freelance writer in Chicago. He does not own shares of any companies mentioned in this article.

None

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

E. I. du Pont de Nemours and Company Stock Quote
E. I. du Pont de Nemours and Company
DD
Monsanto Company Stock Quote
Monsanto Company
MON

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.